by Eric Christianson | Sep 20, 2023 | Endocrine Medication and Disease State Clinical Pearls
A few months back, I compared one of the newest SGLT2 inhibitors in bexagliflozin to the other agents in this class of medication. To sum up my analysis, bexagliflozin provided nothing significantly different from the other SGLT2 inhibitors. In fact, it has less...
